323 related articles for article (PubMed ID: 26298797)
1. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
[TBL] [Abstract][Full Text] [Related]
2. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.
Chow HH; Hakim IA; Vining DR; Crowell JA; Ranger-Moore J; Chew WM; Celaya CA; Rodney SR; Hara Y; Alberts DS
Clin Cancer Res; 2005 Jun; 11(12):4627-33. PubMed ID: 15958649
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals.
Chow HH; Cai Y; Hakim IA; Crowell JA; Shahi F; Brooks CA; Dorr RT; Hara Y; Alberts DS
Clin Cancer Res; 2003 Aug; 9(9):3312-9. PubMed ID: 12960117
[TBL] [Abstract][Full Text] [Related]
4. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E.
Chow HH; Cai Y; Alberts DS; Hakim I; Dorr R; Shahi F; Crowell JA; Yang CS; Hara Y
Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):53-8. PubMed ID: 11205489
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial.
Bellmann-Strobl J; Paul F; Wuerfel J; Dörr J; Infante-Duarte C; Heidrich E; Körtgen B; Brandt A; Pfüller C; Radbruch H; Rust R; Siffrin V; Aktas O; Heesen C; Faiss J; Hoffmann F; Lorenz M; Zimmermann B; Groppa S; Wernecke KD; Zipp F
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33762428
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
de la Torre R; de Sola S; Hernandez G; Farré M; Pujol J; Rodriguez J; Espadaler JM; Langohr K; Cuenca-Royo A; Principe A; Xicota L; Janel N; Catuara-Solarz S; Sanchez-Benavides G; Bléhaut H; Dueñas-Espín I; Del Hoyo L; Benejam B; Blanco-Hinojo L; Videla S; Fitó M; Delabar JM; Dierssen M;
Lancet Neurol; 2016 Jul; 15(8):801-810. PubMed ID: 27302362
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers.
Gee JR; Saltzstein DR; Kim K; Kolesar J; Huang W; Havighurst TC; Wollmer BW; Stublaski J; Downs T; Mukhtar H; House MG; Parnes HL; Bailey HH
Cancer Prev Res (Phila); 2017 May; 10(5):298-307. PubMed ID: 28325826
[TBL] [Abstract][Full Text] [Related]
9. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis.
Dryden GW; Lam A; Beatty K; Qazzaz HH; McClain CJ
Inflamm Bowel Dis; 2013 Aug; 19(9):1904-12. PubMed ID: 23846486
[TBL] [Abstract][Full Text] [Related]
10. Modulation of human glutathione s-transferases by polyphenon e intervention.
Chow HH; Hakim IA; Vining DR; Crowell JA; Tome ME; Ranger-Moore J; Cordova CA; Mikhael DM; Briehl MM; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1662-6. PubMed ID: 17684143
[TBL] [Abstract][Full Text] [Related]
11. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.
Shanafelt TD; Call TG; Zent CS; Leis JF; LaPlant B; Bowen DA; Roos M; Laumann K; Ghosh AK; Lesnick C; Lee MJ; Yang CS; Jelinek DF; Erlichman C; Kay NE
Cancer; 2013 Jan; 119(2):363-70. PubMed ID: 22760587
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
Sinicrope FA; Viggiano TR; Buttar NS; Song LMWK; Schroeder KW; Kraichely RE; Larson MV; Sedlack RE; Kisiel JB; Gostout CJ; Kalaiger AM; Patai ÁV; Della'Zanna G; Umar A; Limburg PJ; Meyers JP; Foster NR; Yang CS; Sontag S
Cancer Prev Res (Phila); 2021 May; 14(5):573-580. PubMed ID: 33648940
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial.
Rust R; Chien C; Scheel M; Brandt AU; Dörr J; Wuerfel J; Klumbies K; Zimmermann H; Lorenz M; Wernecke KD; Bellmann-Strobl J; Paul F
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33622766
[TBL] [Abstract][Full Text] [Related]
15. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.
Kumar NB; Pow-Sang J; Spiess PE; Park J; Salup R; Williams CR; Parnes H; Schell MJ
Oncotarget; 2016 Oct; 7(43):70794-70802. PubMed ID: 28053292
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
Shanafelt TD; Call TG; Zent CS; LaPlant B; Bowen DA; Roos M; Secreto CR; Ghosh AK; Kabat BF; Lee MJ; Yang CS; Jelinek DF; Erlichman C; Kay NE
J Clin Oncol; 2009 Aug; 27(23):3808-14. PubMed ID: 19470922
[TBL] [Abstract][Full Text] [Related]
18. Effects of green tea catechin extract on serum lipids in postmenopausal women: a randomized, placebo-controlled clinical trial.
Samavat H; Newman AR; Wang R; Yuan JM; Wu AH; Kurzer MS
Am J Clin Nutr; 2016 Dec; 104(6):1671-1682. PubMed ID: 27806972
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.
Levin J; Maaß S; Schuberth M; Giese A; Oertel WH; Poewe W; Trenkwalder C; Wenning GK; Mansmann U; Südmeyer M; Eggert K; Mollenhauer B; Lipp A; Löhle M; Classen J; Münchau A; Kassubek J; Gandor F; Berg D; Egert-Schwender S; Eberhardt C; Paul F; Bötzel K; Ertl-Wagner B; Huppertz HJ; Ricard I; Höglinger GU;
Lancet Neurol; 2019 Aug; 18(8):724-735. PubMed ID: 31278067
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
